Market cap
$2.4b
End-of-day close multiplied by current shares on issue.
RYM · NZX
Ryman Healthcare is an NZX-listed healthcare / retirement living company with FY22 - FY26 of published result briefings.
Snapshot
FY26, released 26 May 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $855.6m | ↑ +12.5% |
| EBITDAF | $88.3m | ↑ +94.1% |
| NPAT | -$171.3m | ↑ +60.8% |
| Operating cash flow | $334m | ↓ -18.6% |
| OCF / EBITDAF % | 378.2% | ↓ -523.4pp |
| Net debt | $1.6b | ↓ -5.8% |
| Net debt / EBITDAF | 17.8x | ↓ -51.5% |
| ROE % | -4.2% | ↑ +6.1pp |
| PBT | -$177.6m | ↑ +17.5% |
| FCF pre-lease | $188.3m | ↑ +299.9% |
Source: latest published briefing (FY26, released 26 May 2026). Change compares against the prior equivalent period: FY25, released 29 May 2025.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$2.4b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.17
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
44.6x
Enterprise value compared with recent EBITDA.
P/FCF
12.57x
Market cap compared with recent free cash flow.
P/B
0.58x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Chat
Ask follow-up questions about Ryman Healthcare's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | FY2612 MONTHS26 May 2026 | HY266 MONTHS27 November 2025 | FY2512 MONTHS29 May 2025 | HY256 MONTHS28 November 2024 | HY246 MONTHS29 November 2023 | HY236 MONTHS18 November 2022 | FY2212 MONTHS17 June 2022 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | $855.6m | $413.8m | $760.7m | $366.3m | $323m | $274.2m | $508.8m | Chart |
| Revenue growth % | 12.5% | 13.0% | 10.3% | 13.4% | 17.8%Outside range high revenue growth. 17.8%; 3-period range 10.6% to 13.4%. Revenue growth: 17.8%, above normal range; 3-period mean 12.3%, range 10.6%-13.4%. | 10.6%Outside range low revenue growth. 10.6%; 3-period range 13% to 17.8%. Revenue growth: 10.6%, below normal range; 3-period mean 14.7%, range 13.0%-17.8%. | 11.6% | Chart
|
| EBITDAF | $88.3m | $40.1m | $45.5m | — | $146.3m | — | — | Chart |
| EBITDAF margin % | 10.3% | 9.7% | 6.0% | — | 45.3% | — | — | Chart |
| PBT | -$177.6m | -$40.2m | -$215.4m | $174.8m | $143.4m | $217.3m | $722.1m | Chart |
| PBT growth % | — | — | — | 21.9%Outside range high pbt growth. 21.9%; 3-period range -123% to -20.8%. PBT growth: 21.9%, above normal range; 3-period mean -59.3%, range -123.0%--20.8%. | -34.0% | -20.8% | 75.9% | Chart
|
| NPAT | -$171.3m | -$45.2m | -$436.8m | $94.4m | $186.7m | $194m | $692.9m | Chart |
| NPAT growth % | — | — | — | -49.4% | -3.8%Outside range high npat growth. -3.8%; 3-period range -147.9% to -31.1%. NPAT growth: -3.8%, above normal range; 3-period mean -76.1%, range -147.9%--31.1%. | -31.1% | 63.8% | Chart
|
| Operating cash flow | $334m | $172.9m | $410.3m | $282.8m | $337.9m | $243.7m | $586m | Chart |
| OCF / EBITDAF % | 378.2% | 431.0% | 901.6% | — | 231.0% | — | — | Chart |
| FCF pre-lease | $188.3m | $56.2m | -$94.2m | -$52.5m | -$158.4m | $51.8m | $301.7m | Chart |
| FCF post-lease | $188.3m | $56.2m | -$94.2m | -$52.5m | -$158.4m | — | — | Chart |
| DPS | — | — | — | — | 0.0c | 8.8c | — | Chart |
| Payout ratio vs NPAT % | — | — | — | — | — | 22.7% | — | — |
| ROE % | -4.2% | -1.1%Outside range low roe. -1.1%; 3-period range 2.2% to 10.7%. ROE: -1.1%, below normal range; 3-period mean 5.6%, range 2.2%-10.7%. | -10.3% | 2.2% | 3.8% | 10.7%Outside range high roe. 10.7%; 3-period range -1.1% to 3.8%. ROE: 10.7%, above normal range; 3-period mean 1.6%, range -1.1%-3.8%. | 20.2% | Chart
|
| Net debt | $1.6b | $1.7b | $1.7b | $2.6b | $2.5b | $3b | $2.5b | Chart |
| Net debt / EBITDAF | 17.8x | 41.22x | 36.68x | — | 16.86x | — | — | Chart |
| Debtor days | 11 | 10Outside range low debtor days. 10d; 3-period range 11d to 525d. Debtor days: 10.4 days, below normal range; 3-period mean 306.0 days, range 10.6 days-525.4 days. | 11 | 11 | 382 | 525Outside range high debtor days. 525d; 3-period range 10d to 382d. Debtor days: 525.4 days, above normal range; 3-period mean 134.3 days, range 10.4 days-381.9 days. | 470 | Chart
|
| Inventory days | 0 | 0 | 0 | 1 | 5 | 15Outside range high inventory days. 15d; 3-period range 0d to 5d. Inventory days: 15.4 days, above normal range; 3-period mean 1.9 days, range 0.0 days-4.7 days. | 19 | Chart
|
| Total assets | $12.3b | $12.2b | $12.1b | $12.8b | $13.1b | $12b | $11b | Chart |
Reference: annolyse.ai/companies/rym
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Dividend payout against statutory NPAT.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From PBT collapsed 123% to a NZ$40.2m loss as debt fell NZ$928m
No forward target was supplied. HY25 represented 48.1% of FY25 revenue, but FY25 NPAT of -NZ$436.8m was dominated by an implied second-half fair-value swing of roughly -NZ$531.2m. That makes the FY26 NPAT shape highly contingent on property revaluations rather than trading.
Management cited cost-out tracking ahead of expectations, a refreshed sales strategy, and "significant uplift in average DMF on ORA sales". Those points speak to EBITDAF and cash settlements; none of them resolve the second-half fair-value risk.
Open questions
This briefing cannot assess the full-year fair-value outcome or the durability of the receivables compression without additional disclosure.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 26 May 2026
Operating momentum is real but Ryman remains loss-making at the PBT line, and the FCF swing is partly capex-driven rather than purely earnings-led.
HY26 · Released 27 November 2025
Maiden NZ$56.2m FCF and the balance sheet reset frame the upside, but a NZ$152.7m receivables release flatters the cash result.
FY25 · Released 29 May 2025
Operating recovery is overshadowed by a capex surge to 70.4% of revenue and a -$94.2m free cash outflow.
HY25 · Released 28 November 2024
A tax line that flipped from +30.2% to -46.0% drove the NPAT divergence while pre-lease free cash flow stayed below the historical range at -$52.5m.
HY24 · Released 29 November 2023
Headline NPAT declines just 3.8% on a 30.2% tax credit, but underlying profit is flat and pre-lease cash flow sits well below the historical range.
HY23 · Released 18 November 2022
Underlying profit rose 44.8% but reported NPAT fell 31.1% as receivables expanded and capex jumped 56%, draining cash flow despite revenue growth.
FY22 · Released 17 June 2022
Investment property revaluations drove the headline gain while capex at 55.9% of revenue absorbed most of the operating cash flow expansion.
Get the next Ryman Healthcare result briefing and five-year history updates by email.